Molecular engineering of antibodies for therapeutic and diagnostic purposes
- PMID: 22684311
- PMCID: PMC3499339
- DOI: 10.4161/mabs.20776
Molecular engineering of antibodies for therapeutic and diagnostic purposes
Abstract
During the past ten years, monoclonal antibodies (mAbs) have taken center stage in the field of targeted therapy and diagnosis. This increased interest in mAbs is due to their binding accuracy (affinity and specificity) together with the original molecular and structural rules that govern interactions with their cognate antigen. In addition, the effector properties of antibodies constitute a second major advantage associated with their clinical use. The development of molecular and structural engineering and more recently of in vitro evolution of antibodies has opened up new perspectives in the de novo design of antibodies more adapted to clinical and diagnostic use. Thus, efforts are regularly made by researchers to improve or modulate antibody recognition properties, to adapt their pharmacokinetics, engineer their stability, and control their immunogenicity. This review presents the latest molecular engineering results on mAbs with therapeutic and diagnostic applications.
Figures
Similar articles
-
Toward Drug-Like Multispecific Antibodies by Design.Int J Mol Sci. 2020 Oct 12;21(20):7496. doi: 10.3390/ijms21207496. Int J Mol Sci. 2020. PMID: 33053650 Free PMC article. Review.
-
Engineering the variable region of therapeutic IgG antibodies.MAbs. 2011 May-Jun;3(3):243-52. doi: 10.4161/mabs.3.3.15234. Epub 2011 May 1. MAbs. 2011. PMID: 21406966 Free PMC article. Review.
-
Engineering therapeutic monoclonal antibodies.Immunol Rev. 2008 Apr;222:9-27. doi: 10.1111/j.1600-065X.2008.00601.x. Immunol Rev. 2008. PMID: 18363992 Review.
-
Human monoclonal antibodies from transgenic mice.Handb Exp Pharmacol. 2008;181(181):69-97. doi: 10.1007/978-3-540-73259-4_4. Handb Exp Pharmacol. 2008. PMID: 18071942 Free PMC article. Review.
-
Therapeutic antibodies and antibody fusion proteins.Biotechnol Genet Eng Rev. 2003;20:137-63. doi: 10.1080/02648725.2003.10648041. Biotechnol Genet Eng Rev. 2003. PMID: 14997850 Review. No abstract available.
Cited by
-
DOTAD: A Database of Therapeutic Antibody Developability.Interdiscip Sci. 2024 Mar 26. doi: 10.1007/s12539-024-00613-2. Online ahead of print. Interdiscip Sci. 2024. PMID: 38530613
-
Monoclonal neutralizing antibodies against SARS-COV-2 S protein.Am J Transl Res. 2024 Feb 15;16(2):681-689. doi: 10.62347/ALXM8429. eCollection 2024. Am J Transl Res. 2024. PMID: 38463597 Free PMC article.
-
Structure and Dynamics Guiding Design of Antibody Therapeutics and Vaccines.Antibodies (Basel). 2023 Oct 18;12(4):67. doi: 10.3390/antib12040067. Antibodies (Basel). 2023. PMID: 37873864 Free PMC article. Review.
-
An optimized thermodynamics integration protocol for identifying beneficial mutations in antibody design.Front Immunol. 2023 May 19;14:1190416. doi: 10.3389/fimmu.2023.1190416. eCollection 2023. Front Immunol. 2023. PMID: 37275896 Free PMC article.
-
MutDock: A computational docking approach for fixed-backbone protein scaffold design.Front Mol Biosci. 2022 Aug 29;9:933400. doi: 10.3389/fmolb.2022.933400. eCollection 2022. Front Mol Biosci. 2022. PMID: 36106019 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous